Home
CNSP
CNSP News

Latest CNS Pharmaceuticals Inc. (CNSP) News on September 16, 2025

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

ACCESS Newswire

3 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

ACCESS Newswire

3 months ago

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

ACCESS Newswire

4 months ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire

4 months ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires

4 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

ACCESS Newswire

4 months ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

TipRanks

5 months ago

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

ACCESS Newswire

5 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven?

Simply Wall St.

6 months ago

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven?

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

ACCESS Newswire

6 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

ACCESS Newswire

7 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

ACCESS Newswire

7 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

MT Newswires

7 months ago

CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

ACCESS Newswire

7 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

CNS Pharmaceuticals Announces Reverse Stock Split

ACCESS Newswire

7 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

ACCESS Newswire

7 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

ACCESS Newswire

7 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

ACCESSWIRE

9 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

MT Newswires

10 months ago

CNS Pharmaceuticals Receives More Time to Regain Compliance With Nasdaq Listing Requirement

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

ACCESSWIRE

10 months ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

ACCESSWIRE

a year ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

ACCESSWIRE

a year ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

GlobeNewswire

a year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

ACCESSWIRE

a year ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

ACCESSWIRE

a year ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

MT Newswires

a year ago

CNS Pharmaceuticals Files Prospectus for Sale of Up to 2.4 Million Shares by Stockholders

MT Newswires

a year ago

CNS Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Rule

MT Newswires

a year ago

CNS Pharmaceuticals Prices Direct Offering; Shares Rise

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

MT Newswires

a year ago

Top Midday Decliners

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

CNS Pharmaceuticals Files Registration Statement for $9.2 Million Share, Warrant Offering -- Shares Fall

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

ACCESSWIRE

a year ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Business Insider

a year ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Motley Fool

a year ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Unifor members vote to strike at Manitoba Hydro

CNW Group

a year ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly

AFP

a year ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Business Insider

a year ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

MT Newswires

a year ago

CNS Pharmaceuticals Schedules 1-For-50 Reverse Stock Split This Week

CNS Pharmaceuticals Announces Reverse Stock Split

ACCESSWIRE

a year ago

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

ACCESSWIRE

a year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

CNS Pharmaceuticals to Present at the LSX World Congress 2024

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

ACCESSWIRE

a year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

CNS Pharmaceuticals to Present at Two Investor Conferences in April

ACCESSWIRE

a year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

SaverOne Signs Contract to Install its Systems on 300 Buses of Leading Israeli Transportation Company Bon Tour

PR Newswire

2 years ago

SaverOne Signs Contract to Install its Systems on 300 Buses of Leading Israeli Transportation Company Bon Tour

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

ACCESSWIRE

2 years ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

GlobeNewswire

2 years ago

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting

Fresh Vine Wine, Inc. Signs Definitive Agreement To Acquire Live Entertainment Company Notes Live, Inc.

GlobeNewswire

2 years ago

Fresh Vine Wine, Inc. Signs Definitive Agreement To Acquire Live Entertainment Company Notes Live, Inc.

Lixiang Education Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire

2 years ago

Lixiang Education Regains Compliance with Nasdaq Minimum Bid Price Requirement

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

ACCESSWIRE

2 years ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

ACCESSWIRE

2 years ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

PR Newswire

2 years ago

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Zacks

2 years ago

Akili, Inc. (AKLI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Natural Grocers® Now Hiring for New Store in Incline Village, NV

PR Newswire

2 years ago

Natural Grocers® Now Hiring for New Store in Incline Village, NV

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

GlobeNewswire

2 years ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

GlobeNewswire

2 years ago

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

Are Options Traders Betting on a Big Move in Airgain (AIRG) Stock?

Zacks

2 years ago

Are Options Traders Betting on a Big Move in Airgain (AIRG) Stock?

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%

Zacks

2 years ago

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%

Zedge, Inc. (AMEX:ZDGE) Q1 2024 Earnings Call Transcript

Insider Monkey

2 years ago

Zedge, Inc. (AMEX:ZDGE) Q1 2024 Earnings Call Transcript

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

ACCESSWIRE

2 years ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Red Cat Holdings, Inc. Announces Closing of $9.2 Million Public Offering

GlobeNewswire

2 years ago

Red Cat Holdings, Inc. Announces Closing of $9.2 Million Public Offering

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

ACCESSWIRE

2 years ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Sidoti Events, LLC's Virtual December Small-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Business Wire

2 years ago

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Fresh Vine Wine, Inc. Enters Into Letter of Intent With Live Entertainment and Hospitality Company Notes Live, Inc.

GlobeNewswire

2 years ago

Fresh Vine Wine, Inc. Enters Into Letter of Intent With Live Entertainment and Hospitality Company Notes Live, Inc.

Electra Announces Proposed Amendments to Outstanding Warrants

Business Wire

2 years ago

Electra Announces Proposed Amendments to Outstanding Warrants

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

GlobeNewswire

2 years ago

BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor

Dario Contracts with New Employer for Cardiometabolic Solution

PR Newswire

2 years ago

Dario Contracts with New Employer for Cardiometabolic Solution

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

ACCESSWIRE

2 years ago

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

GlobeNewswire

2 years ago

Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2023

Business Wire

2 years ago

voxeljet AG Reports Financial Results for the Third Quarter Ended September 30, 2023

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

ACCESSWIRE

2 years ago

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

ACCESSWIRE

2 years ago

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Allot to Release Third Quarter 2023 Earnings on November 16, 2023 and Reschedules Conference Call to November 22, 2023

GlobeNewswire

2 years ago

Allot to Release Third Quarter 2023 Earnings on November 16, 2023 and Reschedules Conference Call to November 22, 2023

Xunlei Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2023

GlobeNewswire

2 years ago

Xunlei Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2023

urban-gro, Inc. (NASDAQ:UGRO) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

urban-gro, Inc. (NASDAQ:UGRO) Q3 2023 Earnings Call Transcript

AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807

ACCESSWIRE

2 years ago

AmpliTech to Host Quarterly Investor Call to Review Q3 2023 Earnings on Tuesday November 14, 4:30 PM ET; Dial-in # 1-833-630-0019 or 1-412-317-1807

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Spruce Power Holding Corp Earnings Call

Spruce Power Announces Record Revenue in Third Quarter 2023 Earnings Results

Business Wire

2 years ago

Spruce Power Announces Record Revenue in Third Quarter 2023 Earnings Results

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

GlobeNewswire

2 years ago

Profound Medical to Participate in the Stifel 2023 Healthcare Conference

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

GlobeNewswire

2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Share on Social Networks: